Polivy (polatuzumab vedotin-piiq) / Roche, Pfizer - LARVOL DELTA

Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma. (PubMed, N Engl J Med) - P3 | "Among patients with previously untreated intermediate-risk or high-risk DLBCL, the risk of disease progression, relapse, or death was lower among those who received pola-R-CHP than among those who received R-CHOP. (Funded by F. Hoffmann-La Roche/Genentech; POLARIX ClinicalTrials.gov number, NCT03274492.)."

Journal • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • CD79B

POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): RESULTS FROM THE RANDOMIZED PHASE III POLARGO TRIAL (EHA 2025) - P3 | "Background: Polatuzumab vedotin is approved in frontline and R/R DLBCL, with the latter involving a combination with bendamustine and rituximab (Tilly H, et al. This study met its primary and all key secondary endpoints. Pola-R-GemOx demonstrated a statistically significant and clinically meaningful benefit in OS and PFS, with a 40% reduction in risk of death relative to R-GemOx. Pola-R-GemOx was associated with known risks of individual components, including PN and infection, but neither significantly impacted study endpoints."

Clinical • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pain • Thrombocytopenia

Efficacy and Safety of Glofitamab Plus Polatuzumab Vedotin in Relapsed/Refractory Large B-Cell Lymphoma Including High-Grade B-Cell Lymphoma: Results From a Phase Ib/II Trial. (PubMed, J Clin Oncol) - P1/2 | "Glofit-Pola demonstrated high efficacy and durable responses, with manageable safety, in heavily pretreated patients with R/R LBCL, including patients with HGBCL and previous CAR T-cell therapy failure."

Journal • P1/2 data • B Cell Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Mosunetuzumab plus polatuzumab vedotin in transplant-ineligible refractory/relapsed large B-cell lymphoma: primary results of the phase 3 SUNMO trial. (PubMed, J Clin Oncol) - P3 | "Mosun-Pola demonstrated superior efficacy verus R-GemOx, with significant improvements in both overall response rate and progression-free survival, and infrequent cytokine release syndrome events with a manageable safety profile.(Funded by F. Hoffmann-La Roche Ltd; ClinicalTrials.gov, NCT05171647)."

Journal • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation

Phase II frontline chemolight R-pola-glo trial induces high and durable response rates in elderly and medically unfit/frail patients with aggressive B-cell lymphoma (ASH 2025) - "For this reason, we developed R‑Pola‑Glo, comprising the CD20 antibodyrituximab (R), the antibody‑drug conjugate polatuzumab vedotin (anti‑CD79B; Pola), and the bispecificantibody glofitamab (CD20×CD3; Glo)...Cycle 1 included obinutuzumab, Pola, and step‑up Glo (2.5/10 mg); cycles 2‑6 combined R, Pola,and Glo at 30 mg; cycles 7‑12 consisted of Glo consolidation (30 mg)...Exploratory subgroup analysis suggested that R‑Pola‑Glo efficacy was consistent across allsGA risk groups and mitigated the adverse prognostic impact of classical IPI factors, including LDH.ConclusionsR-Pola-Glo achieved high and durable CMR rates with an expected and manageable safety profile,translating into favorable 1-year survival rates in elderly/frail and medically unfit patients with aggressiveB-cell lymphoma. Compared with other regimens for this population, R‑Pola‑Glo demonstrated higherresponse rates and improved survival outcomes at 1 year, strongly supporting its further..."

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Respiratory Syncytial Virus Infections • CD79B

Severe Anemia, Silent Lymphoma: A Case of High Grade B-Cell Lymphoma Presenting as Profound Anemia (ACG 2026) - "The patient was started on R-CEP (rituximab, cyclophosphamide, etoposide, and prednisone)...Optimal treatment for HGBL-NOS has not been established, however there are several first line regimens, one of which is Pola-R-CHP (polatuzumab-vedotin, rituximab, cyclophosphamide, doxorubicin, prednisone)...Figure: Figure 1: Endoscopy showing multiple cratered ulcers with heaped up margins in the body, fundus and antrum of stomach. Figure: Figure 2: CD20-Positive Tumor Cells on Immunohistochemistry (×20 Magnification)"

Clinical • Anemia • B Cell Lymphoma • Gastrointestinal Disorder • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Peptic Ulcer • Renal Calculi • CD20

Stuck at the Stricture: Capsule Retention Uncovers Triple-Hit Lymphoma (ACG 2026) - "Surgical pathology revealed high-grade B-Cell lymphoma with MYC, BCL2 and BCL6 rearrangements (triple-hit lymphoma), for which he is now receiving chemotherapy with polatuzumab-R-CHP...Capsule retained at stricture site in the terminal ileum. There is erythema, edema (A and B) and oozing blood from abnormal appearing mucosa (C and D) and this was likely the findings seen in the distal ileum on MR enterography."

B Cell Lymphoma • Cardiovascular • Chronic Kidney Disease • Colorectal Cancer • Gastrointestinal Disorder • Hematological Malignancies • High-grade B-cell lymphoma • Hypertension • Lymphoma • Nephrology • Non-Hodgkin’s Lymphoma • Pulmonary Disease • Renal Disease • Small Intestinal Carcinoma • BCL2 • BCL6 • MYC

When Ileitis Isnât Crohnâs Disease (ACG 2026) - "Due to concern for Crohn's disease, patient self-initiated prednisone with symptomatic improvement, followed by exacerbation upon discontinuation...Plans were made to initiate Pola-R-CHP after PET/CT and echocardiographic workup...Figure: Figure 2. Histopathologic Findings"

B Cell Lymphoma • Colorectal Cancer • Crohn's disease • Diffuse Large B Cell Lymphoma • Gastroenterology • Gastroesophageal Reflux Disease • Gastrointestinal Disorder • Hematological Malignancies • Immunology • Inflammatory Bowel Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Sarcoidosis • Small Intestinal Carcinoma

Gastrocolic Fistula and Refractory Ulcer Disease: An Unusual Presentation of Gastrointestinal B-Cell Lymphoma (ACG 2026) - "The patient was started on chemotherapy with 1 cycle of R-CHOP and 5 cycles of Pola-R-CHP. Figure: Abdominal CT scan demonstrating mass-like thickening of the gastric body and fundus, ileocolic lymphadenopathy, and innumerable splenic nodules. Figure: Endoscopic view reviewing (A) sigmoid ulcer, (B) sigmoid fistula, (C) gastric body ulcer and (D) gastric body fistula."

B Cell Lymphoma • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Peptic Ulcer

Chemotherapy-Free Polatuzumab Vedotin and Rituximab (Pola-R) for Frail, Older Patients with Relapsed DLBCL: A Case for Geriatric Assessment and Shared Decision-Making. (PubMed, Reports (MDPI)) - "The patient achieved a complete metabolic response without severe adverse events and has remained progression-free for 15 months. This case illustrates the feasibility and potential clinical activity of the chemotherapy-free Pola-R regimen for frail older patients with DLBCL, underscoring the critical role of integrating GA and SDM to individualize therapy and honor patient goals."

Journal • Alzheimer's Disease • B Cell Lymphoma • Cognitive Disorders • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Improvements in health-related quality of life (HRQoL) in the SUNMO study: Subcutaneous (SC) mosunetuzumab plus polatuzumab vedotin (Mosun-Pola) vs rituximab, gemcitabine and oxaliplatin (R-GemOx) in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after at least one prior therapy (ASH 2025) - P3 | "In SUNMO, Mosun-Pola provided benefits across multiple aspects of HRQoL compared withR-GemOx, particularly in maintaining/improving physical functioning, fatigue, lymphoma symptoms, andPN. Pts treated with Mosun-Pola achieved clinically meaningful improvements in PROs, with scoresexceeding the MCID in several domains and exhibiting a delay in deterioration of >1 year for physicalfunctioning, and >2 months for PN and lymphoma symptoms. Improved PROs with Mosun-Pola vs R-GemOx suggest benefits in HRQoL with chemotherapy-free bispecific antibody combinations."

Clinical • HEOR • B Cell Lymphoma • Gastroenterology • Gastrointestinal Disorder • Gynecologic Cancers • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Peripheral Neuropathic Pain

A Phase 1/1b Study of Parsaclisib Plus Standard Immunochemotherapy for Newly Diagnosed High-Risk Diffuse Large B-Cell Lymphoma (ASH 2024) - "Our group previously reported that addition of the mTOR inhibitor everolimus to R-CHOP resulted in excellent efficacy in the Alliance N1085 trial (Witzig TE et al, Blood Cancer J, 2017, 7(6) : e576), with 23 of 24 patients achieving event-free survival at 24 months (EFS24), supporting further investigation of PI3K/mTOR targeting in DLBCL...Conclusions : Addition of the PI3K inhibitor parsaclisib to R-CHOP or Pola-R-CHP immunochemotherapy is considered safe in patients with newly diagnosed DLBCL. Combination of parsaclisib and standard immunochemotherapy resulted in high ORR and CR rate and encouraging preliminary PFS and OS outcomes patients with high-risk DLBCL. These data support further investigation of PI3K/mTOR targeting in newly diagnosed DLBCL in future trials."

IO biomarker • P1 data • Anemia • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Constipation • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Thrombocytopenia • BCL2 • BCL6 • MYC

Mosunetuzumab Plus Polatuzumab Vedotin vs Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed/Refractory Large B-Cell Lymphoma: Updated Efficacy and Safety From the Phase 3 SUNMO Study Including Second-Line vs Third-Line or Later Patient Subgroups (SOHO 2026) - P3 | "Mosun-Pola continues to show notable efficacy with manageable safety in patients with ASCT-ineligible R/R LBCL, particularly in the 2L setting. 2L: second-line; 3L+: third-line and beyond; ASCT: autologous stem cell transplantation; CI: confidence interval; CR: complete response; CRS: cytokine release syndrome; DOCR: duration of complete response; DoR: duration of response; HR: hazard ratio; ICANS: immune effector cell-associated neurotoxicity syndrome; IRC: Independent Review Committee; LBCL: large B-cell lymphoma; LOT: line of therapy; Mosun-Pola: mosunetuzumab plus polatuzumab vedotin; ORR: objective response rate; OS: overall survival; PFS: progression-free survival; R-GemOx: rituximab, gemcitabine, and oxaliplatin; R/R: relapsed/refractory. This study (NCT05171647) is sponsored by F Hoffmann-La Roche Ltd."

Clinical • P3 data • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Low lymphoma macrophage infiltration predicts poor outcomes for R-CHOP- but not Pola-R-CHP-treated patients with DLBCL. (PubMed, Blood Neoplasia) - P3 | "We aimed to define the key lymphoma microenvironment factors associated with clinical outcomes in patients treated with anti-CD20 (rituximab or obinutuzumab) plus CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; anti-CD20 + CHOP) and to understand how treatment with a modified, ADC-containing chemoimmunotherapy regimen alters the influence of the pretreatment immune landscape on clinical outcome. Our results indicate that ADCs may provide therapeutic benefit to patients with unfavorable immune microenvironments. These trials were registered at www.clinicaltrials.gov as #NCT01287741, #NCT00486759, and #NCT03274492."

Biomarker • Journal • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Polatuzumab Vedotin Plus Rituximab, Gemcitabine, and Oxaliplatin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Results From the Phase III, Randomized POLARGO Trial. (PubMed, J Clin Oncol) - "Pola-R-GemOx significantly improved OS compared with R-GemOx, offering an additional treatment option in patients with transplant-ineligible R/R DLBCL."

Journal • P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Indolent Lymphoma • Infectious Disease • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Novel Coronavirus Disease • Oncology • Pain • Thrombocytopenia • Transplantation

Polatuzumab Vedotin, Rituximab, Ifosfamide, Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (clinicaltrials.gov) - P2 | N=41 | Active, not recruiting | Sponsor: City of Hope Medical Center | Trial completion date: Jul 2026 ➔ Jun 2027

Trial completion date • B Cell Lymphoma • B Cell Non-Hodgkin Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD20

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (ASH 2022) - "We evaluated the safety and efficacy of Pola combined with rituximab, ifosfamide, carboplatin, and etoposide (RICE) as second-line tx in RR DLBCL in a multicenter phase 2 study. PolaR-ICE produced a high ORR with CR in a majority of pts and the safety profile was similar to RICE, without added toxicity due to Pola. Longer follow-up is needed to assess the durability of responses and outcomes following ASCT/Pola consolidation."

Clinical • Anemia • Bone Marrow Transplantation • Cardiovascular • CNS Lymphoma • Constipation • Diffuse Large B Cell Lymphoma • Fatigue • Febrile Neutropenia • Gastroenterology • Gastrointestinal Disorder • Hematological Malignancies • Hypertension • Indolent Lymphoma • Infectious Disease • Leukopenia • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Pain • Renal Disease • Septic Shock • Thrombocytopenia • Transplantation • BCL2 • CD20 • CD79B • CSF3

A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies (clinicaltrials.gov) - P1 | N=340 | Recruiting | Sponsor: Janssen Research & Development, LLC | N=130 ➔ 340 | Trial completion date: Aug 2028 ➔ Oct 2029

Enrollment change • First-in-human • Trial completion date • B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • BCL2 • IRF4

Glofitamab Plus Polatuzumab Vedotin Continues to Demonstrate Frequent and Durable Responses and Has a Manageable Safety Profile in Patients with ≥2L Relapsed/Refractory DLBCL, Including HGBCL, and in Patients with Prior CAR T-Cell Therapy: Updated Results from a Phase Ib/II Study (ASH 2023) - P1/2 | " Patients received obinutuzumab 1000mg on Cycle (C) 1 Day (D) 1 to mitigate the risk of severe cytokine release syndrome (CRS). Glofit+Pola demonstrated high response rates and durable responses in heavily pre-treated patients, the majority of whom were refractory to their last prior therapy, across all histologies, including in patients with HGBCL and those with prior CAR T-cell therapy. The safety profile was manageable and consistent with the individual drugs. The rates of CRS events and AEs potentially consistent with ICANS were low."

CAR T-Cell Therapy • Clinical • P1/2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Oncology • Primary Mediastinal Large B-Cell Lymphoma • CD79B

POLATUZUMAB VEDOTIN, RITUXIMAB, GEMCITABINE AND OXALIPLATIN (POLA-R-GEMOX) FOR RELAPSED/REFRACTORY (R/R) DIFFUSE LARGE B-CELL LYMPHOMA (DLBCL): PHASE III POLARGO TRIAL (ICML 2025) - P3 | "Introduction: Polatuzumab vedotin is approved in frontline and R/R DLBCL; the latter involving combination with bendamustine and rituximab (Tilly et al. Pola-R-GemOx demonstrated a statistically significant and clinically meaningful benefit in OS and PFS, with a 40% reduction in risk of death relative to R-GemOx. Pola-R-GemOx is an alternative treatment option for pts with transplant-ineligible R/R DLBCL not previously exposed to polatuzumab vedotin, which avoids the risk of T-cell depleting regimens and their potential deleterious effects on subsequent therapies."

P3 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Indolent Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Comparative Real-World Outcomes of Chimeric Antigen Receptor T-Cell Therapy vs Standard Systemic Therapy in Diffuse Large B-Cell Lymphoma (SOHO 2026) - "Patients: Adults (≥18 years) with DLBCL receiving CAR-T therapy were compared with those receiving non–CAR-T systemic therapies, including polatuzumab vedotin, tafasitamab, lenalidomide, bendamustine, platinum- or gemcitabine-based regimens, selinexor, or loncastuximab tesirine. In this large real-world propensity-matched cohort, CAR-T therapy was associated with higher long-term mortality and increased healthcare utilization compared with standard therapy. These findings likely reflect differences in patient selection, disease burden, and treatment-related toxicity. Increased ICU utilization and infections highlight the need for improved risk stratification and optimized supportive care in patients undergoing CAR-T therapy."

CAR T-Cell Therapy • Clinical • Real-world • Real-world evidence • Acute Lymphocytic Leukemia • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Hodgkin Lymphoma • Leukemia • Lymphoma • Multiple Myeloma • Non-Hodgkin’s Lymphoma • Oncology

FRONTLINE PHASE II RITUXIMAB-POLATUZUMAB-GLOFITMAB (R-POLA-GLO) TRIAL DEMONSTRATES A MANAGEABLE SAFETY PROFILE AND HIGH RESPONSE RATES IN ELDERLY AND MEDICAL UNFIT PATIENTS WITH AGGRESSIVE LYMPHOMA (EHA 2025) - "R-Pola-Glo combines the anti-CD20 antibody rituximab (R), the antibody-drug conjugate polatuzumab vedotin (anti-CD79B, Pola) and the bispecific antibody glofitamab (CD20×CD3, Glo)...Cycle 1 includes obinutuzumab, Pola, and Glo with step-up dosing (2.5 mg and 10 mg); cycles 2-6 include R, Pola, and Glo at the 30 mg target dose, followed by six cycles of Glo consolidation (30 mg)... R-Pola-Glo demonstrates high EOT CMR rates with manageable safety, warranting its further clinical investigation as a potential first-line treatment option for elderly/frail and medically unfit pts with aggressive lymphoma.* Equal contributions"

Clinical • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Geriatric Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Respiratory Syncytial Virus Infections • CD79B

Early Experience With Glofitamab Plus Polatuzumab Vedotin as Bridging Therapy Prior to CD19-Directed CAR T-Cell Therapy in Relapsed/Refractory Large B-Cell Lymphoma (SOHO 2026) - "Cycle 1: obinutuzumab (1000 mg) or rituximab (375 mg/m2) day 1, Pola (1.8 mg/kg) day 2, Glofit (2.5 mg) day 8 and (10 mg) day 15 in a 21-day cycle...After fludarabine-cyclophosphamide, a single Tali-cel infusion of ≥5 × 106 cells/kg was given... Glofit-Pola BT in R/R LBCL achieved high responses and enabled 93% to proceed to CAR-T therapy. Responses were largely maintained post Tali-cel. BT: bridging therapy, CAR-T: chimeric antigen receptor T-cell therapy, CI: confidence interval, CR: complete response, CRS: cytokine release syndrome, Glofit-Pola: glofitamab and polatuzumab vedotin, ICANS: immune effector cell–associated neurotoxicity syndrome, ICU: intensive care unit, LDH: lactate dehydrogenase, ORR: objective response rate, OS: overall survival, PD: progressive disease, PFS: progression-free survival, R/R LBCL: relapsed/refractory large B-cell lymphoma, SD: stable disease, Tali-cel: talicabtagene autoleucel."

CAR T-Cell Therapy • B Cell Lymphoma • Hematological Malignancies • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma. (PubMed, Ann Hematol) - P=N/A, P2 | "Although based on limited patient numbers, these data may help to contextualize emerging therapies for R/R DLBCL. CLINICAL TRIAL REGISTRATION: NCT04697160 (January 6, 2021)."

HEOR • Journal • Real-world • Real-world evidence • Bone Marrow Transplantation • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Transplantation • CD19

Fixed Duration Mosunetuzumab Plus Polatuzumab Vedotin Has Promising Efficacy and a Manageable Safety Profile in Patients with BTKi Relapsed/Refractory Mantle Cell Lymphoma: Initial Results from a Phase Ib/II Study (ASH 2023) - P1/2 | "Outcomes for R/R MCL pts with PD after the BTKi ibrutinib are very poor, demonstrated by a median overall survival of 2.9 months (Martin et al... Eligible pts had histologically confirmed R/R MCL and had received ≥2 prior regimens (including an anti-CD20 agent, BTKi, and anthracycline- or bendamustine-based therapy)...Ten pts (50%) experienced CRS events; 9 pts experienced Gr 1 events, and 1 pt experienced a Gr 2 event, which was managed with tocilizumab and low-flow oxygen... Fixed-duration Mosun SC in combination with Pola IV induced high CR rates in pts with R/R MCL who had previously received BTKi therapy, including those in high-risk subgroups and those who had received prior CAR T-cell therapy. CRs were observed early and persisted during the follow up period. M-Pola had a manageable safety profile, and all CRS events were low grade."

Clinical • P1/2 data • Alzheimer's Disease • B Cell Non-Hodgkin Lymphoma • CNS Disorders • Fatigue • Hematological Malignancies • Infectious Disease • Lymphoma • Mantle Cell Lymphoma • Musculoskeletal Pain • Non-Hodgkin’s Lymphoma • Ocular Inflammation • Oncology • Ophthalmology • Pain • Pneumonia • Pulmonary Disease • Respiratory Diseases • Uveitis • CD79B • TP53